雷珠單抗治療不同疾病所致黃斑水腫的療效觀察

寇 豆，郝曉琳，張仲臣

?

·臨床研究·

雷珠單抗治療不同疾病所致黃斑水腫的療效觀察

寇 豆1，2，郝曉琳2，張仲臣2

Foundation item:Chinese CASIC 2014 Medical and Health Research Project (No.2014-LCYL-006)

1Graduate School, Jinzhou Medical University, Jinzhou 121001, Liaoning Province, China;2Department of Ophthalmology, Aerospace Central Hospital, Beijing 100049, China

?METHODS: Thirty-eight eyes of thirty-five patients was retrospectively evaluated, twenty-three with ME caused by DM and fifteen with RVO, who received intravitreal ranibizumab (0.5mg/0.05ml) and were followed up for at least a month., The best corrected visual acuity (BCVA), central retinal thickness (CRT) and intraocular pressure(IOP) were followed up at 1, 3d, 1wk and 1mo respectively. The effect of the DME and RVO-ME were compared.

?RESULTS: DME and RVO- ME group after treatment in 1, 3d, 1wk, the BCVA were obviously improved, and the differences were statistically significant (P<0.05). But compared the BCVA in 1mo with before showed no statistically significant difference (P>0.05). DME and RVO-ME group after treatment in 1, 3d, 1wk and 1mo, CRT was obviously improved, and the differences were statistically significant (P<0.05). The BCVA and CRT of treatment showed no statistically significant difference between DME with RVO-ME (P>0.05).

?CONCLUSION: Bevacizumab intravitreal injection for ME caused by DM and RVO was safe and effective.

目的:探討玻璃體腔注射雷珠單抗治療因糖尿病、視網膜靜脈阻塞繼發黃斑水腫的安全及有效性。

方法:選取2013-06/2016-02在北京航天中心醫院眼科因糖尿病繼發黃斑水腫(DME)和視網膜靜脈阻塞繼發黃斑水腫(RVO-ME)收治入院，并符合本研究納入及排除標準的患者35例38眼，其中DME 23眼，RVO-ME 15眼。患眼接受玻璃體腔雷珠單抗(0.5mg/0.05mL)注射治療，治療前和治療后1、3d,1wk、1mo定期門診回訪觀察最佳矯正視力(BCVA)、黃斑中心凹厚度(CRT)、眼壓。比較雷珠單抗治療DME及RVO-ME前后的療效。

結果:DME組及RVO-ME組治療后1、3d,1wk的BCVA均較治療前提高，差異均有統計學意義(P<0.05)，而兩組1mo的BCVA與治療前相比差異均無統計學意義(P>0.05)。DME組及RVO-ME組治療后1、3d,1wk,1mo的CRT均較治療前明顯改善，差異均有統計學意義(P<0.05)。在BCVA及CRT方面比較，雷珠單抗對于RVO-ME及 DME療效差異無統計學意義(P>0.05)。

結論:玻璃體腔注射雷珠單抗對DME及RVO-ME的治療均安全有效。

雷珠單抗；糖尿病黃斑水腫；靜脈阻塞黃斑水腫

引用：寇豆，郝曉琳，張仲臣.雷珠單抗治療不同疾病所致黃斑水腫的療效觀察.國際眼科雜志2016;16(12):2272-2275

0引言

各種疾病所致的黃斑水腫(macular edema ,ME)是引起視力下降的重要原因，糖尿病視網膜病變(DR)、視網膜靜脈阻塞(RVO)是最常見的引起黃斑水腫，造成患者視力下降的疾病，隨著抗血管內皮生長因子(VEGF)的研發及應用，其在黃斑水腫治療上的成就逐步得到人們的認可。2012年初，中國食品與藥物監管部門正式批準雷珠單抗在中國上市，目前應用雷珠單抗治療黃斑水腫已成為研究熱點，近年來多項研究表明，玻璃體腔注射雷珠單抗對DME和RVO-ME均有效，但兩者療效是否存在差異，相關報道并不多。……